Metastatic Castration-Sensitive Prostate Cancer epidemiology report gives a thorough understanding of the Metastatic Castration-Sensitive Prostate Cancer by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. 

Metastatic Castration-Sensitive Prostate Cancer Epidemiology Forecast | Metastatic Castration-Sensitive Prostate Cancer prevalent population

DelveInsight's &lsquo;Metastatic Castration-Sensitive Prostate Cancer (mCSPC) - Epidemiology Forecast&ndash;2032&rsquo; report delivers an in-depth understanding of the disease, historical and forecasted metastatic castration-sensitive prostate cancer (mCSPC) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
<h2>Geography Covered</h2>
<ul>
<li>The United States</li>
<li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)</li>
<li>Japan</li>
</ul>
Study Period: 2019-2032
<h2>Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Disease Understanding and Treatment Algorithm</h2>
Prostate cancer is a type of malignancy that occurs in the prostate gland, which is a part of male reproductive system. Prostate cancer is the 3rd most prevalent type of cancer in the US and the fourth most common worldwide. Approximately 1 in 9 men in the US will be diagnosed with prostate cancer at some point in their lives. As per American Cancer Society, 2019, prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer.
Unlock comprehensive insights! Click Here to Purchase the Full Market Report @ <a href="https://www.delveinsight.com/report-store/metastatic-castration-sensitive-prostate-cancer-mcspc-market">Metastatic Castration-Sensitive Prostate Cancer Treatment Market Size</a>
<h2>Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Recent Developments</h2>
<ul>
<li>In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx&reg; and atezolizumab in mCRPC showed a non-significant improvement in overall survival but met the progression-free survival (PFS) endpoint.</li>
<li>In September 2024, Foundation Medicine received FDA approval for FoundationOne&reg;CDx and Liquid CDx as companion diagnostics for Lynparza&reg; in BRCA-mutated mCRPC.</li>
<li>In July 2024, the ARANOTE trial showed that NUBEQA&reg; plus ADT significantly improved radiological PFS in metastatic hormone-sensitive castrate-resistant prostate cancer (mHSPC).</li>
<li>In July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for metastatic castrate-resistant prostate cancer (mCRPC).</li>
<li>In June 2024, Kangpu Biopharmaceuticals received FDA approval for a Phase II/III trial of KPG-121 with Abiraterone for mCRPC.</li>
<li>In May 2024, Fusion Pharmaceuticals began the Phase 2 AlphaBreak trial of FPI-2265 in mCRPC patients.</li>
<li>In April 2024, Astellas Pharma received European approval for XTANDI&trade; in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC).</li>
<li>In April 2024, FibroGen announced positive Phase 1 trial data for FG-3246 in mCRPC.</li>
<li>On November 16, 2023, the FDA approved enzalutamide (Xtandi) for non-metastatic castration-sensitive prostate cancer (nmCSPC) with high-risk biochemical recurrence.</li>
</ul>
<h2>Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology</h2>
The mCSPC epidemiology division provides insights about historical and current mCSPC patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
<a title="Key Companies Castrate Resistant Prostrate Cancer Pipeline Insights" href="https://www.delveinsight.com/sample-request/metastatic-castration-sensitive-prostate-cancer-epidemiology-forecast"><img src="https://assets.delveinsight.com/delveinsight-meta-images/Key-Companies-Castrate-Resistant-Prostrate-Cancer-Pipeline-Insights.png" alt="Key Companies Castrate Resistant Prostrate Cancer Pipeline Insights" width="1200" height="230" /></a>
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted mCSPC epidemiology [segmented as total prevalent cases of prostate cancer, total diagnosed cases of prostate cancer, age-specific cases of prostate cancer, total diagnosed cases of prostate cancer by clinical stages, total metastatic cases of CSPC and total treated cases of metastatic CSPC in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
<p style="box-sizing: border-box; border: 0px solid #e5e7eb; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-scroll-snap-strictness: proximity; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; margin: 6px 0px; font-size: 15px; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; background-color: #ffffff;"><span style="box-sizing: border-box; border: 0px solid #e5e7eb; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-scroll-snap-strictness: proximity; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; font-weight: 600;">Get More Insights of this Report @&nbsp;<a style="box-sizing: border-box; border: 0px solid #e5e7eb; --tw-border-spacing-x: 0; --tw-border-spacing-y: 0; --tw-translate-x: 0; --tw-translate-y: 0; --tw-rotate: 0; --tw-skew-x: 0; --tw-skew-y: 0; --tw-scale-x: 1; --tw-scale-y: 1; --tw-scroll-snap-strictness: proximity; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; text-decoration-line: none; color: #1b5df3 !important;" href="https://www.delveinsight.com/report-store/prostate-cancer-market-insight">Prostate Cancer Treatment Market Size</a>
<h2>Country Wise mCSPC Epidemiology</h2>
<ul>
<li>Estimates show that the highest cases of mCSPC in the 7MM were in the United States, followed by Japan, Germany, the United Kingdom, Italy, France, and Spain in the year 2021.</li>
<li>As per DelveInsight estimates, the total prevalent population of prostate cancer in the seven major markets was 7,726,394 cases in 2021. The cases in the 7MM are expected to increase during the study period, i.e., 2019&ndash;2032.</li>
<li>As per DelveInsight estimates the diagnosed cases of prostate cancer were highest in the United States. The diagnosed cases of Prostate cancer in 2021 in the US were 1,327,642 cases.</li>
<li>According to the estimated, the United States accounted for 169,647, 738,038, 1,128,665, 525,093, and 131,171 for the age group &le; 54 years, 55-64 years, 65-74 years, 75-84 years, and &gt;84 years in 2021.</li>
<li>In EU5, the total diagnosed prevalent cases of prostate cancer by clinical stages were around 656,570, 378,363, and 77,898 cases for locally advanced (Stage I&ndash;III), biochemical recurrence/progressive, and metastatic, respectively in 2021.</li>
<li>Among EU5 countries, Germany had the maximum total cases of metastatic CSPC with 14,600 cases in 2021 while Spain accounted for the least number of cases. Spain accounted for 4,381 cases of metastatic CSPC in 2021.</li>
<li>As per DelveInsight estimates, treated cases of metastatic CSPC in Japan were 11,094 in 2021.</li>
</ul>
<a title="Metastatic Castration Sensitive Prostate Cancer Epidemiology" href="https://www.delveinsight.com/sample-request/metastatic-castration-sensitive-prostate-cancer-epidemiology-forecast"><img src="https://assets.delveinsight.com/delveinsight-meta-images/Metastatic Castration Sensitive Prostate Cancer Epidemiology.png" alt="Metastatic Castration Sensitive Prostate Cancer Epidemiology" width="800" height="420" /></a>
Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @ <a href="https://www.delveinsight.com/report-store/metastatic-castration-sensitive-prostate-cancer-pipeline-insight">Metastatic Castration-Sensitive Prostate Cancer Treatment Drugs</a>
<h2>Scope of the Report</h2>
<ul>
<li>The report covers the descriptive overview of mCSPC, explaining its causes, signs and symptoms, pathophysiology, and diagnosis</li>
<li>Comprehensive insight has been provided into the mCSPC epidemiology in the 7MM</li>
<li>A detailed review of mCSPC market; historical and forecasted is included in the report, covering drug outreach in the 7MM</li>
<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global mCSPC market</li>
</ul>
<h2>Report Highlights</h2>
<ul>
<li>In the coming years, mCSPC market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market</li>
<li>The companies and academics are working to assess challenges and seek opportunities that could influence mCSPC R&amp;D. The therapies under development are focused on novel approaches to treat/improve the disease condition&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>Major players are involved in developing therapies for mCSPC. Launch of emerging therapies will significantly impact the mCSPC market</li>
<li>A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for mCSPC</li>
<li>Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities</li>
</ul>
<h2>Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Report Insights</h2>
<ul>
<li>Patient Population</li>
<li>Therapeutic Approaches</li>
<li>mCSPC Pipeline Analysis</li>
<li>mCSPC Market Size and Trends</li>
<li>Market Opportunities</li>
<li>Impact of upcoming Therapies</li>
</ul>
<h2>Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Report Key Strengths</h2>
<ul>
<li>11 Years Forecast</li>
<li>7MM Coverage</li>
<li>mCSPC Epidemiology Segmentation</li>
<li>Key Cross Competition</li>
<li>Highly Analyzed Market</li>
<li>Drugs Uptake</li>
</ul>
<h2>Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Report Assessment</h2>
<ul>
<li>Disease Understanding</li>
<li>Current Diagosis Practices and Guidelines</li>
<li>Epidemiology Trends</li>
</ul>
<h2>Key Questions</h2>
<ul>
<li>What is the disease risk, burden and regional/ethnic differences of the mCSPC?</li>
<li>What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?</li>
<li>What is the historical mCSPC patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?</li>
<li>What would be the forecasted patient pool of mCSPC in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?</li>
<li>Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to mCSPC?</li>
<li>Out of all 7MM countries, which country would have the highest prevalent population of mCSPC during the forecast period (2019-2032)?</li>
<li>At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?</li>
</ul>
<h2>Reasons to buy</h2>
<ul>
<li>The report will help in developing business strategies by understanding trends shaping and driving the mCSPC market</li>
<li>To understand the future market competition in the mCSPC market and Insightful review of the key market drivers and barriers</li>
<li>Organize sales and marketing efforts by identifying the best opportunities for mCSPC in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan</li>
<li>Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors</li>
<li>Organize sales and marketing efforts by identifying the best opportunities for mCSPC market</li>
<li>To understand the future market competition in the mCSPC market</li>
</ul>
&nbsp;
Stay Updated with us for Recent Articles
<ul>
<li><a style="color: #e03e2d;" href="https://www.delveinsight.com/blog/metastatic-castration-sensitive-prostate-cancer-market">Exploring the Metastatic Castration-Sensitive Prostate Cancer Market Landscape</a></li>
<li><a style="color: #e03e2d;" href="https://www.delveinsight.com/blog/">Latest DelveInsight Blogs</a></li>
</ul>

1. Key Insights
2. Report Introduction
3. Executive Summary of Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Disease Background and Overview
6.1. Signs and Symptoms of Prostate Cancer
6.2. Risk Factors and Causes of Prostate Cancer
6.3. Pathophysiology of Prostate Cancer
6.4. Prostate Neoplasia
6.5. Genetics of Prostate Cancer
7. Diagnosis of Prostate Cancer
7.1. Screening Tests for Prostate Cancer
7.2. Tests to Diagnose Prostate Cancer
7.3. Stages and Grades of Prostate Cancer
8. Treatment and Management of Prostate Cancer
8.1. Treatment Algorithm of Prostate Cancer
8.2. Observation or Active Surveillance
8.3. Surgery
8.3.1. Open or Laparoscopic Radical Prostatectomy
8.3.2. Risks of Prostate Surgery
8.4. Radiation Therapy
8.4.1. Types of Radiation Therapy
8.5. Hormone Therapy
8.5.1. Types of Hormone Therapy
8.6. Immunotherapy
8.6.1. Vaccine
8.6.2. Immune checkpoint inhibitors
8.7. Chemotherapy
9. American Urological Association (AUA) Guidelines for mHSPC: 2020
10. National Institute for health and care excellence (NICE) Recommendation Guidelines for mCSPC/mHSPC: 2022
11. SEOM Clinical Guidelines for mCSPC/mHNPC: 2021
12. Updated NCCN Guidelines for mCSPC
13. Epidemiology and Patient Population
13.1. Key Findings
13.2. Total Prevalent Cases of Prostate Cancer in the 7MM
13.3. Total Diagnosed Cases of Prostate Cancer in the 7MM
13.4. Total Metastatic Cases of CSPC/HSPC in the 7MM
13.5. Total Treated Cases of Metastatic CSPC/HSPC in the 7MM
13.6. Assumptions and Rationale
13.7. The United States
13.7.1. Total Diagnosed Cases of Prostate Cancer in the United States
13.7.2. Age-specific Cases of Prostate Cancer in the United States
13.7.3. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States
13.7.4. Total Metastatic Cases of CSPC/HSPC in the United States
13.7.5. Total Treated Cases of Metastatic CSPC/HSPC in the United States
13.8. EU-5 Epidemiology
13.8.1. Total Diagnosed Prevalent cases of Prostate Cancer in EU5
13.8.2. Age-specific Diagnosed Prevalent Cases of Prostate Cancer in EU5
13.8.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in EU5
13.8.4. Total Metastatic Cases of CSPC/HSPC in EU5
13.8.5. Total Treated Cases of Metastatic CSPC/HSPC in EU5
13.9. Japan
13.9.1. Total Diagnosed Prevalent cases of Prostate Cancer in Japan
13.9.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan
13.9.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan
13.9.4. Total Metastatic Cases of CSPC/HSPC in Japan
13.9.5. Total Treated Cases of Metastatic CSPC/HSPC in Japan
14. Organizations contributing towards Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
15. Appendix
15.1. Bibliography
16. Report Methodology
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight

DelveInsight's ‘Metastatic Castration-Sensitive Prostate Cancer (mCSPC) - Epidemiology Forecast–2032’ report delivers an in-depth understanding of the disease, historical and forecasted metastatic castration-sensitive prostate cancer (mCSPC) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Metastatic Castration-Sensitive Prostate Cancer - Epidemiology Forecast - 2032

DelveInsight's Metastatic Castration-Sensitive Prostate Cancer - Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology..